The vaginal epithelium provides a barrier to pathogens and recruits immune defenses through the secretion of cytokines and chemokines. Several studies have shown that mucosal sites are innervated by norepinephrinecontaining nerve fibers. Here we report that norepinephrine potentiates the proinflammatory response of human vaginal epithelial cells to products produced by Staphylococcus aureus, a pathogen that causes menstrual toxic shock syndrome. The cells exhibit immunoreactivity for catecholamine synthesis enzymes and the norepinephrine transporter. Moreover, the cells secrete norepinephrine and dopamine at low concentrations. These results indicate that norepinephrine may serve as an autocrine modulator of proinflammatory responses in the vaginal epithelium.
Introduction
Primary and secondary lymphoid tissues, including those constituting the mucosal immune system, are innervated by catecholaminecontaining nerves that originate in paravertebral sympathetic chain ganglia (Elenkov et al., 2000) . Catecholamines, and in particular norepinephrine (NE), can interact directly with leukocytes to regulate innate and adaptive immune responses (Nance and Sanders, 2007; Sanders, 2012) . Within the mucosal immune system, epithelial cells expressing a variety of pathogen recognition receptors play a key role in first-line defense against pathogen invasion at mucosal surfaces (Wira et al., 2005; Ryu et al., 2010; Ashida et al., 2011) . In addition to providing a physical barrier to pathogen entry, these cells secrete and control the thickness and viscosity of a mucus barrier, support a protective commensal microflora population at and above the mucosal surface, and secrete antimicrobial peptides and other effector molecules, including several cytokines and chemokines. As with leukocytes, epithelial cells at many mucosal sites express adrenergic receptors, and NE has been shown to alter epithelial defense functions. These functions include the vectorial secretion of secretory IgA and other defense molecules (Linden, 1996; Schmidt et al., 2007; Gross et al., 2010) , interactions of epithelial cells with bacteria (Green et al., 2003; Chen et al., 2006) , epithelial mucus, ion and fluid transport (Holmgren and Olsson, 2011) , and vectorial cytokine and chemokine secretion (Salathe, 2002; Prause et al., 2003; Chiu et al., 2007; Cox et al., 2007) .
The vaginal and ectocervical mucosae are important sites for the development of infections, including those associated with pathogenic bacteria, such as Staphylococcus aureus, and viruses, such as HIV. Compared to type I mucosal sites in the gut and endocervix that contain a single layer of columnar epithelium, the vaginal mucosa represents a type II mucosal site consisting of stratified, squamous epithelial layers that rely on intercellular lipids instead of tight junctions to create a defensive physical barrier (Iwasaki, 2010; Blaskewicz et al., 2011; Kumamoto and Iwasaki, 2012) . Pathogenic microorganisms must traverse the multi-cellular epithelial barrier to reach the submucosa where immune cells, lymphatic vessels, and blood vessels reside. In some infections of the vaginal tract, pathogens or their exotoxins evoke the release of proinflammatory cytokines and chemokines from mucosal epithelial cells, which act to disrupt barrier function and recruit adaptive immune cells to the mucosa. Staphylococcal superantigens, including toxic shock syndrome toxin-1 (TSST-1), can induce inflammation from the epithelium through the binding of CD40 on epithelial cells (Brosnahan et al., 2008; Spaulding et al., 2012) . This proinflammatory response is thought to recruit T lymphocytes and macrophages to the submucosa, where the superantigens can then activate these adaptive immune cells through the binding of the T cell receptor (TCR) and major histocompatibility complex II (MHC II) to produce a cytokine storm that leads to menstrual toxic shock syndrome (mTSS) (Brosnahan and Schlievert, 2011) . The severe hypotension accompanying this life-threatening syndrome is conventionally offset by treatment with catecholamine-based vasopressor Journal of Neuroimmunology 259 (2013) 8-16 
